Patents by Inventor Nicholas Duesbery

Nicholas Duesbery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anthrax lethal factor is a MAPK kinase protease
    Patent number: 7183071
    Abstract: The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: February 27, 2007
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Nicholas Duesbery, Craig Webb, Stephen Leppla, George Vande Woude
  • Anthrax lethal factor is a MAPK kinase protease
    Publication number: 20060234328
    Abstract: The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
    Type: Application
    Filed: January 5, 2006
    Publication date: October 19, 2006
    Applicant: The Government of the United States of America
    Inventors: Nicholas Duesbery, Craig Webb, Stephen Leppla, George Woude
  • Anthrax lethal factor is a mapk kinase protease
    Patent number: 7056693
    Abstract: The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
    Type: Grant
    Filed: April 22, 2005
    Date of Patent: June 6, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Nicholas Duesbery, Craig Webb, Stephen Leppla, George Vande Woude
  • Anthrax lethal factor is a mapk kinase protease
    Publication number: 20050196822
    Abstract: The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
    Type: Application
    Filed: April 22, 2005
    Publication date: September 8, 2005
    Applicant: The Gov. of the USA as represented by the Secretary of the Dept of Health and Human Services
    Inventors: Nicholas Duesbery, Craig Webb, Stephen Leppla, George Vande Woude
  • Anthrax lethal factor is a MAPK kinase protease
    Patent number: 6911203
    Abstract: The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: June 28, 2005
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Nicholas Duesbery, Craig Webb, Stephen Leppla, George Vande Woude
  • Anthrax lethal factor is a MAPK kinase protease
    Patent number: 6893835
    Abstract: The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: May 17, 2005
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Nicholas Duesbery, Craig Webb, Stephen Leppla, George Vande Woude
  • Anthrax lethal factor is a MAPK kinase protease
    Publication number: 20030096333
    Abstract: The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
    Type: Application
    Filed: March 5, 2002
    Publication date: May 22, 2003
    Inventors: Nicholas Duesbery, Craig Webb, Stephen Leppla, George Vande Woude
  • Anthrax lethal factor is a MAPK kinase protease
    Publication number: 20020187521
    Abstract: The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
    Type: Application
    Filed: March 5, 2002
    Publication date: December 12, 2002
    Inventors: Nicholas Duesbery, Craig Webb, Stephen Leppla, George Vande Woude
  • Anthrax lethal factor is a MAPK kinase protease
    Patent number: 6485925
    Abstract: The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: November 26, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Nicholas Duesbery, Craig Webb, Stephen Leppla, George Vande Woude